2012 International Human Microbiome Congress Paris 19‐21 Mars
The conference is the third event organized under the banner of the IHMC, and follows Shenzhen 2010 (organized by the MetaHIT consortium, with BGI Shenzhen) and Vancouver 2011 (organized by the NIH and the Foundation for the National Institutes of Health ‐ Canada?).
The goals of the International Human Microbiome Consortium (IHMC) is to work under a common set of principles and policies to study and understand the role of the human microbiome in the maintenance of health and causation of disease and to use that knowledge to improve the ability to prevent and treat disease. The Consortium's efforts are focused on generating a shared comprehensive data resource that will enable investigators to characterize the relationship between the composition of the human microbiome (or of parts of the human microbiome) and human health and disease. The IHMC is open, at any time, to the funders and PIs of human microbiome research programs that have the capacity to mount a comprehensive analysis of the human microbiome in health and/or disease, and that agree to carry out their efforts according to a set of commonly agreed‐upon IHMC policies The principles, structure and operating modes of the IHMC were defined progressively through several meetings organized since November 2005. The IHMC was officially launched at its meeting held in Heidelberg on October 15‐16 2008. For additional information about the IHMC, please visit www.human‐microbiome.org. The 2012 conference is
and supported by the European Commission (grant HEALTH‐F4‐2007‐201052).
Join the conversation on twitter using the hashtag #IHMC2012
Paris, France –March 19‐21 2012
International H
uman
Microbiom
e Co
ngress ‐ Ag
enda
9:00 ‐ 11:00 REGISTRATION
11:00 ‐ 11:45 Welcome speeches Marion GUILLOU, President & CEO INRA, France Pascale BRIAND, General Director, ANR, France Rudolf STROHMEIER, Deputy Director General, DG Research and Innovation, European Commission
11:45 ‐ 12:30 Keynote
Chair: Julian DAVIES (UBC, Canada)
S. Dusko EHRLICH (INRA, France) Lessons from the MetaHIT project
12:30 ‐ 14:00 Lunch ‐ Posters
14:00 ‐ 16:30 APPROACHES TO MICROBIOME ANALYSIS
Chair: SØren BRUNAK (CBS Denmark Technical University, Denmark)
14:00 ‐ 14:30 Rob KNIGHT (University of Colorado, USA) Sources of variation in the human microbiome
14:30 ‐ 15:00 LI Junhua (BGI Shenzhen, China)Improvement of microbial gene catalog construction
15:00 ‐ 15:30 Karen E. NELSON (J. Craig Venter Institute, USA) Reference genomes for the study of the Human Microbiome
15:30 ‐ 16:00
16h00 ‐ 16:15
16h15 ‐ 16:30
H. Bjørn NIELSEN (CBS Denmark Technical University, Denmark) MetaGenomic Species: facilitating statistical and biological interpretation Mathieu ALMEIDA (INRA, France) From "meta‐genomic species" to high quality draft genomes Mircea PODAR (Oak Ridge National Laboratory ‐ Univ. of Tennessee, USA) Uncovering the dark matter of the human microbiota through high throughput single cell genomics and targeted pangenomics
16:30 ‐ 17:00 Coffee Break
19 March 2012
Paris, France –March 19‐21 2012
International H
uman
Microbiom
e Co
ngress ‐ Ag
enda
19 March 2012
17:00 ‐ 18:45 DATA ORGANISATION & INTERPRETATION
Chair: Lita PROCTOR (National Institutes of Health, USA)
17:00 ‐ 17:30
17:30 ‐ 18:00
Owen WHITE (University of Maryland, USA)The Human Microbiome Project analysis infrastructure Jens NIELSEN (Chalmers University of Technology, Sweden) Prospects for systems biology and modeling of the gut microbiome
18:00 ‐ 18:30 Manimozhiyan ARUMUGAM (EMBL, Germany)Towards petabase metagenomics : challenges and roadblocks ahead
18:30 ‐ 18:45 Dan KNIGHTS (University of Colorado, USA)Human‐associated microbial signatures: examining their predictive value
19:00 ‐ 21:00 Wine & Cheese Buffet ‐ Poster Session
20 March 2012
9:00 ‐ 10:45
MICROBIOME IN HEALTHY INDIVIDUALS 1
Chair: Jane PETERSON (National Institutes of Health, USA)
9:00 ‐ 9:30 Dirk GEVERS (The Broad Institute, USA) Baseline for a healthy human microbiome
9:30 ‐ 10:00 Mihai POP (University of Maryland, USA) Can we and should we assemble metagenomes?
10:00 ‐ 10:30 Curtis HUTTENHOWER (Harvard School of Public Health, USA) Reducing microbial unemployment: functional roles for the microbiome in health and disease
10:30 ‐ 10:45 Masahira HATTORI (University of Tokyo, Japan)Metagenomics of Japanese gut microbiomes
10:45 ‐ 11:15 Coffee Break
Paris, France –March 19‐21 2012
International H
uman
Microbiom
e Co
ngress ‐ Ag
enda
20 March 2012
11:15 ‐ 12:30
MICROBIOME IN HEALTHY INDIVIDUALS 2
Chair: Maria GIOVANNI (National Institutes of Health, USA)
11:15 ‐ 11:45 Kristine WYLIE (Washington University Genome Institute, USA) Novel Bacterial Taxa in the Human and Vervet Microbiomes
11:45 ‐ 12:15 Paul W. O'TOOLE (APC University College Cork, Ireland) Diet‐health‐microbiota interactions in older persons
12:15 ‐ 12:30 Christian HOFFMAN (University of Pennsylvania, USA) Long term dietary patterns shape gut microbial enterotypes
12:30 ‐ 14:00 Lunch ‐ Posters 13:15 ‐ 13:45 Seminar power calculations for designing microbiome experiments
14:00 ‐ 16:15 MICROBIOME IN DISEASE 1Chair: Karsten KRISTIANSEN (University of Copenhagen, Denmark)
14:00 ‐ 14:30 Oluf PEDERSEN (Hagedorn Research Institute, Denmark) Deep metagenomic sequencing demonstrates marked differences in the gut microbiome between lean and obese people: evidence from the MetaHIT obesity study
14:30 ‐ 15:00 Karine CLEMENT (Institute of Cardiometabolism & Nutrition, INSERM‐UPMC‐APHP, France) Gut metagenome: clinical investigation studies
15:00 ‐ 15:30 Liping ZHAO (Shanghai Jiao Tong University, China) “Microbiome‐Wide Association studies,MiWAS” for dissecting the role of gut microbiota in metabolic syndrome, from animal models to human trials
15:30 ‐ 16:00
WANG Jun (BGI Shenzhen, China) A Metagenome‐Wide Association Study of gut microbiota identifies markers associated with Type 2 Diabetes
16:00 ‐ 16:15 LI Lanjuan (Zhejiang University, China) The intestinal dysbiosis and its contribution to NAFLD in human and the high‐fat induced rats
16:15 ‐ 16:30 Kjersti AAGAARD (Baylor College of Medicine, USA)A comprehensive metagenomic catalogue of microbiota across body sites in primates: a high fat maternal diet alters the offspring microbiome to 1 year of age
16:30 ‐ 17:00 Coffee break
Paris, France –March 19‐21 2012
International H
uman
Microbiom
e Co
ngress ‐ Ag
enda
20 March 2012
17:00 ‐ 19:15 MICROBIOME IN DISEASE 2
Chair: Per BRANDTZAEG (Oslo University Hospital, Norway)
17:00 ‐ 17:30 Francisco GUARNER (Hospital Univeristari Vall d’Hebron, Spain) Distortion of the gut microbial ecosystem in patients with ulcerative colitis
17:30 ‐ 18:00 Brandi L. CANTAREL (University of Maryland, USA) Identification of Crohn’s signatures in the human gut microbiota by meta‐omics
18:00 ‐ 18:30 James VERSALOVIC & Emily HOLLISTER (Texas Children’s Hospital, USA) Network analysis reveals altered community structure in the fecal microbiota of children with irritable bowel syndrome
18:30 ‐ 18:45 Jacques RAVEL (University of Maryland, USA) Transcriptional dynamics of the vaginal microbiome
18:45 ‐ 19:15 Melody SLASHINSKI (Baylor College of Medicine, USA) Ethical, legal and social dimensions of human microbiome research
19:45 Gala Dinner in the nave of Palais Brongniart
21 March 2012
9:00 ‐ 10:45 MICROBIOME MODULATION
Chair: Annick MERCENIER (Nestlé Research Center, Switzerland)
9:00 ‐ 10:30 Muriel DERRIEN (Danone Research, France) Impact of consumption of a fermented milk product on gut microbiota stability and functionality in ulcerative patients
9:30 ‐ 10:00 David A. RELMAN (Stanford University, USA) Stability and resilience in the human microbiome
10:00 ‐ 10:30 Willem de VOS (Wageningen University, The Netherlands) From associations to causality: effect of treatments targeting the human intestinal microbiome
10:30 ‐ 10:45 Paul COTTER (University College Cork, Ireland) Modulation of the gut microbiota; antibiotics vs. bacteriocins
10:45 ‐ 11:00 Coffee break
Paris, France –March 19‐21 2012
International H
uman
Microbiom
e Co
ngress ‐ Ag
enda
21 March 2012
11:15 ‐ 12:30 FUNCTIONS OF MICROBIOME 1
Chair: Emmanuelle MAGUIN (INRA, France)
11:15 ‐ 11:45 Joël DORÉ (INRA, France) Screening of metagenomic clones
11:45 ‐ 12:15 B. Brett FINLAY (University of British Columbia, USA) The role of microbiota in enteric and allergic diseases
12:15 ‐ 12:30 Marion LECLERC (INRA, France) Riboflavin production by a metagenomic clone from the human ileum mucosa: a new role for Faecalibacterium prausnitzii in vivo?
12:30 ‐ 14:00
Lunch – Posters
14:00 ‐ 15:30 FUNCTIONS OF MICROBIOME 2
Chair: Baghi SINGH (Canadian Institutes of Health Research, Canada)
14:00 ‐ 14:30 Stephen M. COLLINS (McMaster University Medical Center, Canada) The influence of the intestinal microbiota on the gut‐brain axis
14:30 ‐ 15:00 Martin J. BLASER (New York University, USA) Effects of early‐life antibiotics on murine developmental phenotypes and immunity
15:00 ‐ 15:15 James GOEDERT (National Cancer Institute NIH, USA) Fecal microbial determinants of fecal and systemic estrogens
15:15 ‐ 15:30 Iradj SOBHANI (UPEC‐Paris XII, France) Putative role of gene mutation and environment in colon cancer inflammation in host
15:30 ‐ 16:15 MICROBIOME DATA CHALLENGES
Peer BORK (EMBL, Germany)Complexity and individuality of human gut microbiomes
16:15 ‐ 16:45 Coffee Break
Paris, France –March 19‐21 2012
International H
uman
Microbiom
e Co
ngress ‐ Ag
enda
21 March 2012
16:45 ‐ 18:30 MICROBIOME FUTURE Panel discussion on the future of Human Microbiome Research
Debate moderator: Ed YONG, UK Funding agencies…
Patrik KOLAR, European Commission Marc OUELETTE, Canadian Institutes of Health Research, Canada Lita PROCTOR, National Institutes of Health, USA …Industry… Pierre BELICHARD, Entérome, France Christian BRECHOT, Institut Mérieux, France Johan VAN HYLCKAMA VLIEG, Danone Research, France ...Ethical & social issues Lucy HOAREAU, UNESCO Richard SHARP, Cleveland Clinic, USA
18:30 Closing remarks
2012 International Human Microbiome Congress Posters
All posters will be on exhibition on the ground floor of the Palais throughout the conference.
Posters 1-91, Notre Dame des Victoires Author Title Number Abdollahi-Roodsaz S. Critical role of mouse microbiota and efficacy of dietary non-digestible oligosaccharide
treatment in Th17-dependent autoimmune destructive arthritis 81
Alexeev D.G. Human gut microbiota analyzed by mass-spectrometry and sequencing 57
Azad M.B. Exclusive breastfeeding protects against Clostridium difficile colonization by promoting lower relative abundance of Lachnospiraceae in gut microbiota.
5
Ballarini A. Species-level profiling of human microbiomes with the BactoChip microarray 68
Beighton D. In vivo expression of glycan utilization genes by Streptococcus oralis and Streptococcus mitis in the oral cavity.
15
Belzer C. Function and importance of Akkermansia spp. in the intestinal tract 28
Brown J.R. Antibacterial Drug Modulation of the Gut Microbiome in Obesity and Diabetes Animal Models
82
Budding A.E. Evaluation of rectal swabs for the analysis of human intestinal microbiota 54
Budding A.E. Automated high througput analysis of the intestinal microbiota by IS-pro 53
Bülow E. Functional metagenomic analysis reveals selection for antibiotic resistance in the gut microbiota during Intensive Care hospitalization
86
Campbell A.G. Single cell genomics of uncultured oral Chloroflexi, Deltaproteobacteria and Synergistes 39
Campbell J.H. Single-cell genomic characterization of human oral representatives of the incultured SR1 and TM7 bacterial phyla.
47
Chen Yu Association of oral health, oral bacterial infection, and gastric precancerous lesions 70
Chunlei Chen Antioxidant-Protective Effects of Lactitol against Endotoxemia in Patients with Chronic Viral Hepatitis
85
Claesson M.J. Resolving Additional Microbiota Subtypes in Intestinal Microbiota of Older Subjects 4
Couvigny B. The commensal bacterium Streptococcus salivarius inhibits PPARγ activity and its target genes in human intestinal epithelial cells.
33
Cox L.M. Early life microbiota alters adult metabolism and body composition 1
Danilenko V.N. The Toxin-Antitoxin System Gene Polymorphism As A Marker for Species and Strain Identification of the Probiotic Component of Human Microbiome
19
Davenport E. Examining the genetic basis of interindividual variation in the human fecal microbiome 12
de Leeuw M. 16S metagenomics profiling 72
2012 International Human Microbiome Congress Posters
Author Title Number Di Liberto G. Functional analysis of the predicted surface proteome of Gram+ bacteria from the human
GI tract. 59
Do Thuy Evidence of ethanolamine catabolism by Fusobacteria. 29
Earl A. The Most Wanted Bacteria from the Human Microbiome 73
Eloe-Fadrosh E.A. Effects of oral immunization with the Ty21a typhoid vaccine on the gut microbiota and local and Systemic immune responses
87
Feehery G.R. Novel purification reagents for the study of the human microbiome 48
Flores R. Effect of Delayed Freezing on Microbial Composition in Human Feces: Lessons for Epidemiological Studies
42
Francino P. Meconium microbiota types: relation to maternal and childbirth determinants and to health outcomes in early childhood
2
González A. Assessing temporal changes in microbial communities. 6
Guédon E. Relationship between self-aggregation property of the human commensal bacterium Streptococcus salivarius and its ability to interact with intestinal epithelial cells
20
Haiser H.J. Characterizing the inactivation of the cardiac drug, digoxin, by a member of the human gut microbiota
30
Han S. Artificial Polyploidy Improves Genome Coverage from Single Cell 56
Hao Qin A mouse fecal microbial gene catalogue established by Illumina-based sequencing 55
Hettich R. A hybrid metagenomic sequencing and assembly approach increases proteome identification coverage in the human gut microbiome
49
Hooda S. Fecal microbiota of healthy adult men is affected by novel dietary fibers and correlated with fecal metabolites
89
Isaksen M.L. GA-map™ - a rapid, comprehensive gut microbiota analysis 51
Jalanka-Tuovinen J. Intestinal microbiota in healthy adults: dimensions of the common core and relation to intestinal symptoms
65
Jeffery I.B. Microbial diversity is highly correlated with the Healthy Food Diversity Index 90
Kaci G. Anti-inflammatory properties of commensal Streptococcus salivarius on human intestinal epithelial cells and in murine TNBS-induced colitis model
21
Keijser B.J.F. A public-private partnership that aims to establish a novel, multivariate view of oral health 43
Kolmeder C. Effects of a probiotic intervention on the human intestinal metaproteome 91
Kong, Ling-Chun Associations between gut microbiota and adipose tissue gene expression during bariatric surgery induced weight loss in morbid obesity
18
Konya T. Is house dust a reservoir for gut bacteria? 7
Kotowska D. Changes in gut microbiota in resveratol treated and exercised aged mice. 75
Kushugulova A.R. Study of the properties of bacteria of the genus Lactobacillus, representatives of intestinal microbiota
22
2012 International Human Microbiome Congress Posters
Author Title Number Lahti L. Global characterization of the human intestinal microbiota by integrative meta-analysis 67
Langella P. Analysis of anti-inflammatory effects of FaecalibacteriumI prausnitzii using gnotobiotic mice
24
Layec S. Impact of surface-exposed proteins on the commensal life in Streptococccus salivarius. 23
Lewis C.M. Characterizing Extinct Gut Microbiomes 50
Li Huiying Propionibacterium acnes strain populations in the skin microbiome associated with acne 32
Luang-In V. Influence of human gut microbiota on the metabolic fate of glucosinolates 34
Luna R.A. Temporal characterization of the gut microbiome in a cohort of hospitalized preterm infants
8
Ma Jun Initial association study of human microbiome profile with its host mitochondria genome variants
13
Mackie, R.I. Transcriptional analysis of wheat arabinoxylan hydrolysis and utilization by Bacteroides ovatus and Bacteroides intestinalis
38
Maukonen J. The currently used commercial DNA extraction methods give different results of Clostridial and Actinobacterial populations derived from human fecal samples
63
Maurice C.F. An active subset of the human gut microbiome responsive to xenobiotics 58
Morrison M. Weight loss associated dietary intervention affects the human gut microbiota in obese but otherwise healthy Australian males and changes in the growth of Faecalibacterium praunitzii in response to changes in nutrient profiles
83
Morrison M. A “metaparental mating” approach for the recovery of new transconjugant strains of human gut bacteria
84
Murugkar P.P. Mechanisms of Uncultivability in the Oral Microbiome 60
Pieper D. The anterior nare microbial community over space and time
31
Putignani L. Succession of early microbial consortia in the developing infant intestinal microbiota unveiled by meta-omics approaches
9
Renault P. Prevalence of Streptococci in the intestinal flora 25
Rho M. CRISPRs: Evolving immune systems in human microbiomes 44
Roeselers G. A Top-down microbial systems ecology view of the impact of prebiotic oligosacharides on Bifidobacteria in a Human gut microcosm
16
Roger L. Monitoring the Effects of Black Tea Polyphenols on the Human Intestinal Microbial Ecosystem in vitro
76
Salojärvi J. Meta-analysis of the Human Gut Microbiota - Focus on Enterotypes 66
Scheffer-Wong A. Massively Parallel Synthesis of Oligonucleotides Enables Fluorescence In Situ Hybridization (FISH) to Microbial Genomes
41
Schioppa T. Probiotic and postbiotic activity in health and disease: comparison on a novel polarized ex-vivo organ culture model.
77
Seekatz A. The Effect of an Oral Live-attenuated Shigella Vaccine and Wild type Shigella Infection on the Intestinal Microbiota of Cynomolgus Monkeys
74
2012 International Human Microbiome Congress Posters
Author Title Number Shah P. A biomolecular isolation framework for molecular Eco-Systems Biology of the human
microbiome 64
Sim K. Missing bifidobacteria: systematic undercounting in neonatal gastrointestinal microbiota resolved with novel, universal, barcoded 454 primers.
40
Sonne S.B. Modulation of the gut microbiota by diets and the anti-inflammatory drug indomethacin in obesity prone and obesity resistant mice
78
Spencer M.D. Robust data management and analysis strategies overcome sequencing platform idiosyncrasies
69
Spinler J.K. Pangenomic analysis of Lactobacillus reuteri highlights the evolution of a human-specific ecotype
35
Srivastava T. Complete genome sequences of rat and mouse strains of unculturable Segmented Filamentous Bacteria, a potent inducer of Th17 cell differentiation.
36
Stamboliyska R. Identification of prokaryotic transposable elements from metagenomic marine data 52
Thiele I. Systems biology approach to the human–Bacteroides thetaiotaomicron symbiosis 37
Thompson H. An in-vitro model system for the cultivation of previously uncultured human oral bacteria 61
Tims S. Development of a carbohydrate binding protein detection assay 45
Tomida S. The pan-genome and strain diversity of Propionibacterium acnes in the human skin microbiome
26
Tyler A.D. Interaction of IBD-associated genetic polymorphisms and the microbiome of the pelvic pouch
11
Ubeda C. Commensal anaerobic bacteria mediate Vancomycin-resistant Enterococcus clearance from the intestine.
17
Vallès Y. Acquisition and development of the gut microbiota 3
Wacklin P. Secretor genotype (FUT2 gene) is associated with composition of bacteria in the human intestine
14
Wang Duochun Genome sequencing reveals unique mutations in characteristic metabolic pathways and the transfer of virulence genes between V. mimicus and V. cholerae
10
Wang Xinhui Patterns on the composition of nasopharyngeal microbiota 27
Ward D.V. Impact of antibiotic administration on the establishment and development of infant gut flora
79
Witt K. Identifying mechanisms of bacterial unculturability in the human gut microbiome 62
Xiang C. Vaginal microbiota restoration for bacterial vaginosis treated with metronidazole and probiotic Lactobacillus intravaginally
88
Yamanishi S. Down-regulation of mucosal immune system in mice exposed to early life antibiotic treatments
80
Yang Liying Reproducibility and accuracy of amplicon-based 16S rRNA gene surveys 71
Yow M.A. Pathogen discovery in prostate cancer: a massively parallel sequencing approach 46
2012 International Human Microbiome Congress Posters
Posters 92-170, Espace Réaumur
Author Title Number Aagaard K. A 16S-Based Metagenomic approach to characterisation of the vaginal microbiome
signature in pregnancy 137
Abnet C.C. Upper digestive tract microbiome diversity is associated with total mortality in a prospective cohort study in China
164
Alban M. Life on human surfaces: skin metagenomics. 128
Alekseyenko A.V. Association of cutaneous microbiota with psoriasis 126
Alicki E. The impact of IgA on the intestinal microbiome 92
Aliferis C.F. Microbiomic Signatures of Psoriasis: Feasibility and Methodology Comparison 136
Batto JM Optimizations to compute large correlation matrix onto GPU system of hybrid HPC clusters
108
Biesbroek G The nasopharyngeal microbiota in relation to 7-valent Pneumococcal Conjugate Vaccination: a randomized controlled trial in healthy children in The Netherlands
162
Biesbroek G Effect of Feeding type on the Composition and Dynamics of Nasopharyngeal Microbiota in Infants.
160
Biesbroek G Viral and Bacterial Interactions in the Upper Respiratory tract of Healthy Children: a metagenomic approach
161
Bylova N.A. Gut microbiota in chronic heart failure (CHF) 120
Charlson E.S. Biogeography of microbial populations in the respiratory tract of healthy and HIV-infected subjects
144
Cheng J. Duodenal epithelium associated microbiota in pediatric coeliac disease patients and healthy controls assessed by microbial phylogenetic microarray
171
Chiang H-I Hybrid assembly of metagenomic and single-cell genome sequencing data 150
Collison M. A data integration platform for the microbiota 110
Dols J.A.M. Bacteria associated with bacterial vaginosis in HIV-positive Tanzanian women: Correlation analysis between results from 16S-rDNA-based microarrays, microscopy and Whiff tests
140
Durbán A. Follow-up of faecal microbiota in irritable bowel syndrome patients. 148
Durbán A. Dynamics of faecal bacterial communities based on daily follow-up 147
Dutilh B.E. Towards the human colorectal cancer microbiome 151
Faust K. Prediction of relationships between microbial taxa in the human body 96
Fettweis J.M. The vaginal microbiome: disease, genetics and the environment 130
Fouad A.F. Transformation of oral microbiome from normal oral cavity to acute endodontic infections 127
2012 International Human Microbiome Congress Posters
Author Title Number Fricke W.F. The fungal and bacterial microbiome of the stomach 152
Gajer PM. Association between cigarette smoking and the vaginal microbiota 129
Ganu R. Linking barkers hypothesis on the developmental origins of adult disease with the hygiene hypothesis: maternal methyl-donor supplementation (MDS) significantly alters the fetal liver microbiome
141
Ganu R. Remote history of maternal infection or asymptomatic vaginosis alters the human placental microbiome
142
Garcia-Garcerà M. Staphylococcus prevails in the skin microbiota of long-term immunodeficient mice. 125
Gorkiewicz G. Dysbiosis and altered mucosal immune response in chronic inflammatory upper gastrointestinal (GI) diseases.
138
Hendriksen W.T. Modeling pathways of nasopharyngeal microbiota of young children based on 16S rRNA sequence data: an exploratory study
100
Hildebrand F. Combining a gut-specific annotation platform with a dedicated datamining pipeline towards understanding obese and IBD microbiota
114
Hunter C. EBI Metagenomics: Studying the Functions of Metagenomes. 101
Huot Creasy The Data Analysis and Coordination Center for the Human Microbiome Project 99
Joossens M. Functional Repercussions of Subclinical Intestinal Dysbiosis In Unaffected Relatives Of Crohn’s Disease Patients
157
Karlsson F. Atherosclerosis is associated with an altered gut metagenome 143
Kistler J.O Bacterial Composition of Dental Plaque during the Transition from Health to Experimentally Induced Gingivitis
145
Ko G.P. Investigation of Vaginal Microbiota in a Korean Twin Cohort 135
La Rosa P.S. Modeling and Clustering Taxonomic Trees from Human Microbiome Data using Statistical Object-Oriented Data Analysis
103
Langille M.G.I. Inferring microbial community function from taxonomic composition 102
Mai V. Fecal Microbiota Distortions Appear Associated with Late Onset Sepsis in Preterm Infants 153
Mändar R Effect of sexual intercourse on vaginal microbiome of infertile couples’ women 131
Manichanh C A robust microbiota: a key protagonist against functional intestinal disorders? 167
Manichanh C Storage conditions of intestinal microbiota matter in functional metagenomics 166
Miller C.S. EMIRGE: Sensitive, quantitative microbial community characterization via deep sequencing and assembly of full-length 16S amplicons.
105
Minot S. The human gut virome: Inter-individual diversity, genomic hypervariation, and dynamic response to diet
154
2012 International Human Microbiome Congress Posters
Author Title Number Nakayama J. Asian Microbiome Project: A pilot study on the basal microbiota profile of healthy Asian
youngsters 139
Nookaew I. Enterotype analysis of 317 gut genomes 113
Obregón-Tito A.J. Metagenomics and social inclusion in Peru 165
Ogilvie L.A. Comparative (meta)genomic analysis and ecological profiling of human gut-specific bacteriophage ɸB124-14.
168
Patsantara G. Parasitic helminth Enterobius vermicularis as a commensal microorganism 169
Pérez-Brocal V. An approach to the characterization of the human virome in Crohn’s disease 155
Pesole G. SARMA: a web resource for species assignment of high-throughput sequencing reads from
Metagenomics Analysis
106
Philllips G.J. Dysbiosis characterised by reduced abundance of Roseburia is associated with increased
severity of colitis in Il-10-/- mice
146
Pinto J.M. Sinonasal Microbiota Vary with Disease Subtype: Implications for Mucosal Inflammatory
Disorders of the Upper Airway
156
Plichta D.R. Functional analysis of novel genetic structures indentified through metagenomics of
human gut.
115
Popenko A.S. MALINA - a Web-service for human gut microbiota whole-genome metagenomic reads
analysis
94
Potluri S. & Prifti E. Gut Microbiome and Immunome of NTR Twins 123
Qin Nan Analysis of gut microbiome in patients with liver cirrhosis 158
Raes J Microbiome variation in health and disease: how to get more out of your metagenome. 111
Redel H. Quantitation of cutaneous microbiota in diabetic and non-diabetic men 159
Riehle K. The Genboree Microbiome Toolset and Microbiome Analysis 107
Said H.S. Comparative Analysis of Salivary Microbiota of IBD Patients and Healthy Individuals using
Barcoded Pyrosequencing
116
Sanz A Genetic risk of developing coeliac disease and milk-feeding type influence the intestinal
colonization pattern in infants. The PROFICEL study
122
Saulnier D.M. Volatile metabolite production and microbiome composition in halitosis 117
Schmieder R. Tools for Detecting Antibiotic Resistance in the Human Microbiome 95
Segal L.N. Evaluation of the upper airway and lung microbiome in emphysema 118
Segata N. Efficient metagenomic community profiling enables species-level characterization of over 250 shotgun sequenced gut microbiomes
104
Sharma V.K. Comparative Analysis of MetaBin with Other Homology-based Methods for Taxonomic Assignments of Metagenomic Sequences
97
2012 International Human Microbiome Congress Posters
Author Title Number Sharpton T.J. Quantifying Human Microbiome Functional Variation using Operational Protein Families 109
Shoaie S. Saeed Modeling of human gut microbiome 93
Smith A.M. Development of a hierarchical taxonomy assignment pipeline for fungal microbiomics 98
Stahringer S.S. A longitudinal survey of the oral microbiota in adolescent twins 133
Tong M. Defining a mosaic of functional microbial communities at the human mucosal surface, and their association with IBD
149
Treangen. T. A modular and open source metagenomic assembly pipeline 112
Tyakht A.V. Examining composition of Russian human gut microbiota by assessing relative abundance of functional and taxonomical units
163
Vincent C. The intestinal microbiota as a predictor for nosocomial Clostridium difficile infection 119
Winek K. The impact of focal cerebral ischaemia on the composition of murine intestinal microbiota 121
Wylie K.M. The Human Virome in Healthy Adults 170
Youmans B. Alterations in the human gut microbiome during and after norovirus-associated travelers’ diarrhea
132
Zaura E. The relation between oral Candida load and bacterial microbiome profiles in Dutch elderly 124
Zhou Xia Characterization of Microbiota in External Urogenital and Perianal Areas of Women 134
2012 International Human Microbiome Congress Sponsors
The conference was organized with the support of our Sponsors. We are particularly grateful to Danone Research, HP, Proctor & Gamble, NIH HMP, Lenovo & NVIDIA, Major Sponsors of the 2012 edition.
Danone was born out of a conviction that now lies at the very heart of its stated mission: "Bringing health through food to as many people as possible". The Group's strong ambitions rest primarily on the mobilisation and skills of its R&D teams. Its R&D know-how is housed by Danone Research, a worldwide organisation present in some 15 countries that brings together around 1,200 staff, with a network of almost 200 scientific collaborations worldwide generating knowledge in specific fields (prebiotics, probiotics, human breast milk, immunology, metabolic programming, etc). Danone is active in four fields: fresh milk products (No. 1 worldwide), water (No. 2 worldwide for bottled water), baby nutrition (No 2 worldwide) and medical nutrition. Visit us at www.danone.com
The NIH Human Microbiome Project is building a vast community resource of taxonomic and metagenomic sequences of microbiomes across major body regions of healthy adults, reference strain genome sequences and disease-specific properties of microbiomes in urogenital, skin and gut diseases. Computational tools and technologies along with microbiome-specific ELSI studies are providing additional resources for the field. Please visit commonfund.nih.gov/hmp/ for the latest information on the project.
HP for Health and Life Sciences helps organizations across the value chain deploy systems that improve business and health outcomes through the capture, management, and integration of information related to bioscience innovation, pharmaceuticals, medical technology, and patient data. HP's extensive portfolio of printing and personal computing products and IT services, software and solutions enable health and life science organizations to lower costs, speed innovation into practice, function more efficiently and improve the quality of care. HP Health and Life Sciences industry solutions enable collaboration across the entire ecosystem and mine more value from market players and information. More information about HP Health and Life Sciences is available at www.hp.com/go/healthandlifesciences
Lenovo (HKSE:992) (ADR: LNVGY) is a $US21 billion personal technology company serving customers in more than 160 countries, and the world's second-largest PC vendor. Dedicated to building exceptionally engineered PCs and mobile internet devices, Lenovo's business is built on product innovation, a highly-efficient global supply chain and strong strategic execution. Formed by Lenovo Group's acquisition of the former IBM Personal Computing Division, the company develops, manufactures and markets reliable, high-quality, secure and easy-to-use technology products and services. Its product lines include legendary Think-branded commercial PCs and Idea-branded consumer PCs, as well as servers, workstations, and a family of mobile internet devices, including tablets and smart phones. Learn more about Lenovo workstations at www.lenovo.com/thinkstation
Four billion times a day, P&G brands touch the lives of people around the world. P&G is marketing probiotics in the United States for Personal Health Care (Align®) and Pet Care (Prostora®) and is exploring additional new product possibilities. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Pampers®, Tide®, Ariel®, Always®, Whisper®, Pantene®, Mach3®, Bounty®, Dawn®, Gain®, Pringles®, Charmin®, Downy®, Lenor®, Iams®, Crest®, Oral-B®, Duracell®, Olay®, Head & Shoulders®, Wella®, Gillette®, Braun® and Fusion®. The P&G community includes approximately 127,000 employees working in about 80 countries worldwide. Please visit www.pg.com for the latest news and in-depth information about P&G and its brands.
2012 International Human Microbiome Congress Sponsors
Paris-based Enterome is a privately owned personalized medicine company dedicated to the development of drugs and biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine. Enterome's technology was developed initially in the INRA laboratory of S. Dusko Ehrlich at Jouy-en-Josas, France. Enterome is currently advancing an internal pipeline of biomarkers in chronic serious diseases i.e. metabolic diseases: NASH, type-2 diabetes, obesity and inflammatory bowel diseases, Crohn's disease and ulcerative colitis. Learn more about Enterome at www.enterome.com
LABIP, the Industry Platform for EU sponsored research programs on lactic acid bacteria, is a European Economical Association of industries involved in the production of products using lactic acid bacteria and probiotics and have production or research facilities within the EU. Companies that fulfill these criteria have the right to become a member and cannot be excluded. At the moment LABIP has 25 members. The focus of LABIP is on the interaction between Academia (universities and research institutions) and Industry (more specifically Industry R&D) in the field of (pre-competitive) scientific and technological research on lactic acid bacteria, gut microbiota and the interaction between microbiota and the host. LABIP aims to: • Secure EU-funding for LAB research on a long-term basis in Europe • Act as platform where industrial researchers in the area of LAB and microbiota
can meet and interact with scientist from Academia • Coordinate communication about topics of industrial relevance between
science, industry and EU authorities Visit for more information www.labip.com
Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products.
www.lifetechnologies.com
MO BIO offers a complete line of nucleic acid purification kits optimized for the isolation of microbial DNA and RNA from a variety of inhibitor rich sample types including gut, stool, cervical swabs, human skin, soil, biofilm, water, and bacterial cultures utilizing a patented enzyme Inhibitor Removal Technology®. We also offer the widest selection of bead homogenization options for lysis of any micro-organism including the multi-velocity high efficiency PowerLyzer™ sample homogenizer.
2012 International Human Microbiome Congress Sponsors
Nestlé, founded in 1866, is the world’s leading Nutrition, Health and Wellness Company. With headquarters in Vevey, Switzerland, Nestlé employs over 280,000 people, with factories and operations in almost every country of the world. The driving force of innovation within Nestlé is its dynamic network of Research, Development and Technology centres worldwide. Comprised of leading scientists, technicians and engineers, these centres cultivate diverse research and development expertise to respond to ever-changing consumer and business needs. At the heart of this Nestlé Research Network lies the Nestlé Research Center (NRC), the world’s largest private food and nutrition research institute and the centre of fundamental scientific research within Nestlé. Learn more about Nestlé Science & Research at www.research.nestle.com
NVIDIA awakened the world to computer graphics when it invented the GPU in 1999. From its roots in visual computing, the company expanded into parallel and mobile computing. One of the most complex processors ever created, the GPU is the engine of computer graphics: the science and art of using technology to create and enjoy beautiful, interactive experiences. NVIDIA has shipped over one billion GPUs.
Learn more about NVIDIA at www.nvidia.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Unilever is one of the world's leading suppliers of fast-moving consumer goods. Our products are sold in over 180 countries and used by 2 billion consumers every day. Our vision is help people feel good, look good and get more out of life with brands and services that are good for them and good for others. We will inspire people to take small everyday actions that can add up to a big difference for the world. We will develop new ways of doing business that will allow us to double the size of our company while reducing our environmental impact. We work with 167,000 employees worldwide. We produce world leading brands such as Knorr, Lipton, Hellmann's, Becel, Dove, Axe and Pond's, and brands and innovation are at the heart of everything we do. Visit for more information www.unilever.com.
Visit our sponsors in the poster exhibition area
2012 International Human Microbiome Congress Acknowledgements
This conference was organized by the MetaHIT Consortium, as part of its task defined in the grant agreement HEALTH‐F4‐2007‐201052 financed by the European Commission under the 7th framework program. The consortium gathers 13 partners from academia and industry, from a total of 8 countries. Its total cost has been evaluated at more than 21,2 million € and the funding from the European Commission has been set with an upper limit of 11,4 million €. The project started 1 January 2008 and will last until 30 June 2012. To learn more about the project and our achievements, please visit www.metahit.eu
We wish to thank the following individuals for graciously contributing their time and expertise.
Scientific organization Committee
• Peer BORK • Julian DAVIES • Joël DORÉ • S. Dusko EHRLICH • Francisco GUARNER • Masahira HATTORI
• Karen E. NELSON • Jane PETERSON • Lita PROCTOR • Bhagirath SINGH • George WEINSTOCK • Liping ZHAO
Local organization : Jean‐Michel BATTO, Quitterie DUPUTEL, Florence HAIMET, Petar KOS, Rachel KOUANDA,
Marielle POUGNON & Yohanan WINOGRADSKY
Local organization was realized by coordinator of the MetaHIT project.